HOUSTON--(BUSINESS WIRE)--In a significant development for the treatment of acute ischemic stroke, the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), awarded the first $4 million of a grant budgeted to total approximately $30 million to researchers at the Keck School of Medicine of the University of Southern California (USC) to conduct a pivotal Phase 3 clinical trial using ZZ Biotech’s experimental treatment for acute ischemic stroke. The drug, 3K3A-APC, which is a genetically engineered variant of the naturally occurring activated protein C (APC), is proposed to protect the brain following a stroke by reducing bleeding and inflammation, and by blocking the cell death process in neurons, glia, and endothelial cells.
HOUSTON--(BUSINESS WIRE)--ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The study is being conducted at Macquarie University, in Sydney, Australia, and seeks to investigate whether 3K3A-APC is safe and potentially effective in patients with ALS. The Firies Climb for Motor Neurone Disease provided an AU$1 million donation to support this clinical trial.